



ROBERT M. DAY, Ph.D., DIRECTOR

K A N S A S

KATHLEEN SEBELIUS, GOVERNOR

DIVISION OF HEALTH POLICY AND FINANCE

**State of Kansas Medicaid Program
Drug Utilization Review Board Meeting**

May 10, 2006, 10:00 am

*EDS/White Lakes Mall
Wichita/Kansas City Room
3600 SW Topeka Blvd, Suite 204
Topeka, Kansas 66611*

Open Session Agenda (revised)

- I.** Call to Order
- II.** Announcements
- III.** Review and Approval of March 8, 2006 Meeting Minutes
- IV.** Old Business
 - A.** Prior Authorization Unit Report (Revised)
 - B.** Celebrex®
 - 1.** Update Prior Authorization Criteria
 - 2.** Public Comment (5 minutes)
 - 3.** DUR Board Recommendation

**State of Kansas Medicaid Program
Drug Utilization Review Board Meeting
May 10, 2006**

Open Session Agenda -- Page 2 of 3

V. New Business

A. Pro-DUR

- 1. High Dose Alerts- Flonase®, Elastat®, Maxair Autohaler®, Seasonale®, Vitamin B-12 injection**

A. Public Comment

B. DUR Board Recommendation

- 2. Dose Optimization**

A. Public Comment

B. DUR Board Recommendation

- B. Update Prior Authorization Criteria for TB Drugs/Diagnosis Codes (Isoniazid, Ethambutol, Pyridoxine, Pyrazinamide, Aminosalicyclic acid, Ethionamide, Capreomycin, Cycloserine)**

- 1. Update Prior Authorization Criteria/Diagnosis Code Exclude Edit**

- 2. Public Comment (5 minutes)**

- 3. DUR Board Recommendation**

- C. Nuvigil® (armodafinil) Diagnosis Code Restrictions**

- 1. Diagnosis Code Restriction Proposal**

- 2. Public Comment (5minutes)**

- 3. DUR Board Recommendation**

- D. Discussion/Approval of PDL and Resulting PA Criteria for Non-preferred Drugs**

- 1. Human Growth Hormone**

a. PDL Advisory Committee Recommendations

b. DHPF Proposal for Preferred Drugs and PA Criteria

c. Public Comment (5 minutes)

d. Discussion

e. DUR Board Recommendation

- 2. Adjunct Antiepileptics**

a. PDL Advisory Committee Recommendations

b. DHPF Proposal for Preferred Drugs and PA Criteria

c. Public Comment (5 minutes)

d. Discussion

e. DUR Board Recommendation

**State of Kansas Medicaid Program
Drug Utilization Review Board Meeting
May 10, 2006**

Open Session Agenda -- Page 3 of 3

3. Fibric Acid Derivatives
 - a. PDL Advisory Committee Recommendations
 - b. DHPF Proposal for Preferred Drugs and PA Criteria
 - c. Public Comment (5 minutes)
 - d. Discussion
 - e. DUR Board Recommendation

4. New Inhaled Corticosteroids
Asmanex®
 - a. PDL Advisory Committee Recommendations

5. Novel Sleep Agents
Rozerem®
 - a. PDL Advisory Committee Recommendations

E. Announcements

VI. Adjournment

Informal comments will be accepted from members of the audience at various points in the agenda.

****Lunch for Committee Members 12:00-12:45 pm****

+NEXT MEETING: July 12, 2006